Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 1/20 | 0.44 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.44 |
| ▸ | PGR | P06401 | 1/20 | 0.44 |
| ▸ | SCD | O00767 | 1/20 | 0.41 |
| ▸ | KCNJ1 | P48048 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.37 |
| ▸ | CTSS | P25774 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 1/20 | 0.37 |
| ▸ | HTR7 | P34969 | 2/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.36 |
| ▸ | PNMT | P11086 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1769324 | 0.89 | PGR (0.46) | SIRT6PGRSCDVCAM1OPRM1 | |
| SCHEMBL2814643 | 0.85 | ALDH1A1 (0.44) | PGRSCDOPRM1 | |
| SCHEMBL3047350 | 0.85 | PGR (0.43) | PGRSCDOPRM1 | |
| SCHEMBL2815633 | 0.84 | ALDH1A1 (0.43) | PGRSCDOPRM1 | |
| SCHEMBL2876866 | 0.81 | PDE4A (0.41) | PGRSCDOPRM1 | |
| SCHEMBL3897910 | 0.81 | L3MBTL1 (0.44) | SIRT6PGRSCDKCNJ1CTSL | |
| SCHEMBL5475184 | 0.80 | SCD (0.42) | SIRT6PGRSCDOPRM1 | |
| SCHEMBL2302830 | 0.75 | OPRM1 (0.40) | OPRM1 | |
| SCHEMBL651535 | 0.75 | OPRM1 (0.58) | OPRM1 | |
| SCHEMBL3151326 | 0.75 | OPRM1 (0.58) | OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9394289-B2 | Inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA NV (BE) | 2016-07-19 | — | — | US | disclosed |
| US-9394289-B2 | Inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA NV (BE) | 2016-07-19 | — | — | US | disclosed |
| US-9394289-B2 | Inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA NV (BE) | 2016-07-19 | — | — | US | disclosed |
| EP-2016070-B1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2016-01-13 | — | — | EP | disclosed |
| EP-2016070-B1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2016-01-13 | — | — | EP | disclosed |
| CN-101472914-B | C-FMS kinase inhibitors | JANSSEN PHARMACEUTICA NV | 2015-05-20 | — | — | CN | disclosed |
| EP-2376491-B1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON INC (US) | 2015-03-04 | — | — | EP | disclosed |
| US-20140378457-A1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2014-12-25 | — | — | US | disclosed |
| US-20140378457-A1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2014-12-25 | — | — | US | disclosed |
| US-20140378457-A1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2014-12-25 | — | — | US | disclosed |
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| EP-2376491-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | Cephalon, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010071885-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2010-06-24 | — | — | WO | disclosed |
| CN-101472914-A | C-FMS kinase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2009-07-01 | — | — | CN | disclosed |
| EP-2016070-A1 | INHIBITORS OF C-FMS KINASE | Janssen Pharmaceutica, N.V. (BE) | 2009-01-21 | — | — | EP | disclosed |
| WO-2007124319-A1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-01 | — | — | WO | disclosed |
| WO-2007124319-A1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-01 | — | — | WO | disclosed |
| US-20070249680-A1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-10-25 | — | — | US | disclosed |
| US-20070249680-A1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-10-25 | — | — | US | disclosed |
| US-20070249680-A1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378457-A1 | INHIBITORS OF C-FMS KINASE | MUSK, FRK, FES | ADRB1 2710/4885SIRT6 4656/4885PGR 1322/4885 |
| US-20070249680-A1 | INHIBITORS OF C-FMS KINASE | MUSK, FRK, FES | ADRB1 2710/4885SIRT6 4656/4885PGR 1322/4885 |
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | JAK2, ALK, ABL1 | ADRB1 3478/4885SIRT6 3364/4885PGR 2631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.